Alzheimer’s & Dementia
News
New Diagnostic Tool Approved for Evaluation of Dementia Patients
Zac Haughn, Senior Associate Editor
March/April 2012—Amyvid, which indicates levels of beta-amyloid plaques in the brain, can help guide the diagnosis of dementia.
Dementia Insights: Toward New Clinical Criteria for Alzheimers Disease and Mild Cognitive Impairment
Ronald Devere, MD
September/October 2010—One development from this summer’s International Conference on Alzheimers Disease is progress toward new criteria for Alzheimers and MCI.
Diagnosing And Treating Co-Morbid Sleep Apnea In Neurological Disorders
Erik K. St. Louis, MD
July/August 2010—Since neurologists are frequently principal care providers for many neurological patients, it is crucial for neurology physicians to be familiar with the identification of sleep apnea. First of a two part series.
Preserving Memory: Tips to Help Baby Boomers Stay in the Game
Majid Fotuhi, MD, PhD
March/April 2009—Middle-aged patients may unnecessarily fear dementia. These 10 tips can help preserve cognitive function.
Are We Overlooking B-12 Deficiency as a Cause of Dementia?
Ronald Devere, MD
March/April 2009—Frequently sought as a cause of dementia, B-12 deficiency is considered a clinically uncommon cause. Appropriate assessment may detect deficiency's role in certain cases.
A Complete Approach to Dementia Management
Zac Haughn, Associate Editor
January 2009—The theft of cognitive function is the calling card of dementia. But neurologists must recognize and manage other aspects of this disease that can be of immeasurable importance in maintaining quality of life.
Olfactory Testing in the Diagnosis of Alzheimer's Disease and Other Neuro-Degenerative Disorders
Ronald Devere, MD
July/August 2009—Olfactory testing can be a convenient and relatively inexpensive method to gather supporting information for the diagnosis of neuro-degenerative diseases.
Pipeline Watch: Promising Developments Reported
Several recent reports highlight progress in the development of new therapeutic agents for Parkinson's, Alzheimer's, and stroke. While final market approval could still be yea…
